Around the Precinct: 30 April 2020

Cracking the immunity code of COVID-19, support for Australia’s first clinical vaccine trials and World Malaria Day 2020 – this week at the Alfred Research Alliance.

Prof Anne Holland, Monash University

Prof Anne Holland from Monash University has developed an at-home rehabilitation program to help those with respiratory illness.

Alfred Health

Cracking the code on COVID-19
Dr James McMahon, Infectious Diseases physician and Head of Clinical Research at the Alfred Hospital and Monash University, has his sights set on cracking the immunity code of COVID-19.
Read more

Monash University – Central Clinical School

Monash program offering at-home care for patients with lung and respiratory conditions
Monash telehealth research is able to help both COVID-19 and non-COVID patients with lung illnesses to manage their condition while in home isolation during the pandemic lockdown.
Read more

Cracking the COVID-19 immunity code 
Monash University’s Dr James McMahon, an infectious disease expert and hospital clinician at The Alfred and Monash Health, is leading the development of a biobank aimed at cracking the immunity code of COVID-19.
Read more

Numbercrunching to find a stable target for inhibiting the SARS-CoV-2 virus
In the absence of a vaccine or an approved effective therapy against COVD-19, there is an interest in repositioning existing drugs or developing new inhibitors against viral targets.
Read more

International study highlights diabetes risks in COVID-19
A Lancet review has found elderly people with diabetes who contract COVID-19 are at a much higher risk of dying from the disease – and the virus may actually trigger diabetes onset in normally healthy people.
Read more

Burnet Institute

Global COVID-19 pandemic: latest
The Australian Government, like others around the world, is rolling out major public health strategies aimed at reducing the spread of the coronavirus.
Read more

Burnet to advise on ACT safe injecting facility
Burnet Institute has been commissioned to investigate the need for a medically supervised safe injecting facility in Canberra.
Read more

New study explores COVID impact on drug use
Burnet is a collaborator in a new study exploring the impact of the COVID-19 pandemic on the experiences of Australians who use illicit drugs.
Read more

Statement of support for Papua New Guinea
Burnet Institute reaffirms its support for, commitment to, and solidarity with the people of Papua New Guinea during the global COVID-19 pandemic.
Read more

Eliminating malaria in the time of COVID-19
On World Malaria Day 2020, it’s never been more important to stay focused on our collective efforts to control and eliminate malaria.
Read more

COVID-19 tests under the microscope
Professor Brendan Crabb on the need for accurate and reliable tests to help manage the transition away from community lockdowns for COVID-19.
Read more


360biolabs supports the first Australian COVID-19 clinical vaccine trials
In one of the first COVID-19 clinical vaccine trials, US-based clinical-stage biotechnology company Novavax has selected Australian speciality laboratory 360biolabs, to conduct sample analysis for the clinical trial of its SARS-CoV-2 recombinant spike protein nanoparticle vaccine, NVX-CoV2373.
Read more